Education
About Us
Working with TipRanks
Follow Us
Clover Biopharmaceuticals Ltd. (HK:2197)
:2197
RESEARCH TOOLSreports
2197 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$0.19 - HK$0.62
Previous CloseN/A
Volume1.38M
Average Volume (3M)6.08M
Market Cap
HK$713.38M
Enterprise ValueHK$138.55M
Total Cash (Recent Filing)HK$427.53M
Total Debt (Recent Filing)¥89.64M
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Aug 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding1,297,062,400
10 Day Avg. Volume15,346,300
30 Day Avg. Volume6,083,434
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-0.27
Price to Sales (P/S)0.00
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$0.50Price Target Upside-1.96% Downside
Rating ConsensusHold
Number of Analyst Covering0
Clover Biopharmaceuticals Ltd. News
PremiumCompany Announcements
Clover Biopharmaceuticals Announces Board and Committee Changes
PremiumCompany Announcements
Clover Biopharmaceuticals Launches Phase I Trial for New Respiratory Vaccines
PremiumCompany Announcements
Clover Biopharmaceuticals Ends Distribution Agreement with Adimmune
PremiumCompany Announcements
Clover Biopharmaceuticals Faces Arbitration Over $224 Million Claim
PremiumCompany Announcements
Clover Biopharmaceuticals Announces 2025 Annual General Meeting AgendaPremiumCompany Announcements
Clover Biopharmaceuticals Grants Options and RSUs to Boost Talent Retention2197 FAQ
What was Clover Biopharmaceuticals Ltd.’s price range in the past 12 months?
Clover Biopharmaceuticals Ltd. lowest stock price was HK$0.18 and its highest was HK$0.62 in the past 12 months.
What is Clover Biopharmaceuticals Ltd.’s market cap?
Clover Biopharmaceuticals Ltd.’s market cap is HK$713.38M.
When is Clover Biopharmaceuticals Ltd.’s upcoming earnings report date?
Clover Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 20, 2025 which is in 22 days.
How were Clover Biopharmaceuticals Ltd.’s earnings last quarter?
Clover Biopharmaceuticals Ltd. released its earnings results on Mar 31, 2025. The company reported -HK$0.717 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.717.
Is Clover Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clover Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Clover Biopharmaceuticals Ltd. pay dividends?
Clover Biopharmaceuticals Ltd. does not currently pay dividends.
What is Clover Biopharmaceuticals Ltd.’s EPS estimate?
Clover Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clover Biopharmaceuticals Ltd. have?
Clover Biopharmaceuticals Ltd. has 1,297,062,400 shares outstanding.
What happened to Clover Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Clover Biopharmaceuticals Ltd. reported an EPS of -HK$0.717 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12%.
Which hedge fund is a major shareholder of Clover Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:2197
Clover Biopharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$0.50 (-1.96% Downside)
HK$0.50 (-1.96% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-62.62%
Trailing 12-Months
Company Description
Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Technical Analysis
Kintor Pharmaceutical Ltd
―
HBM Holdings Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―